APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1&PD-L1 Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PD-1&PD-L1 Immunotherapy Industry Growth and Trends Forecast to 2032

2 January 2026101 pages

Choose your research edition.

Industry ResearchPD-1&PD-L1 Immunotherapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1&PD-L1 Immunotherapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal PD-1&PD-L1 Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1&PD-L1 Immunotherapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1&PD-L1 Immunotherapy Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PD-1&PD-L1 Immunotherapy include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc. and Innovent Biologics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PD-1&PD-L1 Immunotherapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PD-1&PD-L1 Immunotherapy market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PD-1&PD-L1 Immunotherapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PD-1&PD-L1 Immunotherapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PD-1&PD-L1 Immunotherapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PD-1&PD-L1 Immunotherapy Market by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer Inc.

Jiangsu HengRui Medicine Co., Ltd.

GlaxoSmithKline plc

Regeneron Pharmaceuticals Inc.

Innovent Biologics, Inc.

F. Hoffmann-La Roche Ltd

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Bristol-Myers Squibb Company

BeiGene, Ltd.

AstraZeneca Plc

PD-1&PD-L1 Immunotherapy Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1&PD-L1 Immunotherapy Segment by Application

Non-Small Cell Lung Cancer

Hepatocellular Carcinoma

Urothelial Carcinoma

Esophageal Cancer

Small Cell Lung Cancer

Others

PD-1&PD-L1 Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1&PD-L1 Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1&PD-L1 Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1&PD-L1 Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PD-1&PD-L1 Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of PD-1 Inhibitors Table 2. Major Company of PD-L1 Inhibitors Table 3. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 5. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type (2021-2026) Table 6. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 7. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type (2021-2026) Table 8. Global PD-1&PD-L1 Immunotherapy Price by Type (2021-2026) & (US$/Unit) Table 9. Global PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 10. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type (2027-2032) Table 11. Global PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (US$ Million) Table 12. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type (2027-2032) Table 13. Global PD-1&PD-L1 Immunotherapy Price by Type (2027-2032) & (US$/Unit) Table 14. North America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 15. North America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 16. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 17. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 21. Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (US$ Million) Table 24. PD-1&PD-L1 Immunotherapy Industry Trends Table 25. PD-1&PD-L1 Immunotherapy Industry Drivers Table 26. PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges Table 27. PD-1&PD-L1 Immunotherapy Industry Restraints Table 28. Global PD-1&PD-L1 Immunotherapy Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company (2021-2026) Table 30. Global PD-1&PD-L1 Immunotherapy Sales by Company (2021-2026) & (K Units) Table 31. Global PD-1&PD-L1 Immunotherapy Sales Share by Company (2021-2026) Table 32. Global PD-1&PD-L1 Immunotherapy Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global PD-1&PD-L1 Immunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global PD-1&PD-L1 Immunotherapy Major Company Production Sites and Headquarters Table 35. Global PD-1&PD-L1 Immunotherapy Company, Product Type & Application Table 36. Global PD-1&PD-L1 Immunotherapy Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global PD-1&PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global PD-1&PD-L1 Immunotherapy Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (K Units) Table 41. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2021-2026) Table 42. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (US$ Million) Table 43. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2021-2026) Table 44. Global PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032) & (K Units) Table 46. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2027-2032) Table 47. Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032) & (US$ Million) Table 48. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2027-2032) Table 49. Global PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 52. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application (2021-2026) Table 53. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 54. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application (2021-2026) Table 55. Global PD-1&PD-L1 Immunotherapy Price by Application (2021-2026) & (US$/Unit) Table 56. Global PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 57. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application (2027-2032) Table 58. Global PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (US$ Million) Table 59. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application (2027-2032) Table 60. Global PD-1&PD-L1 Immunotherapy Price by Application (2027-2032) & (US$/Unit) Table 61. North America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 62. North America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 63. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 64. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 68. Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (US$ Million) Table 71. Sanofi S.A. Company Information Table 72. Sanofi S.A. Business Overview Table 73. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio Table 75. Sanofi S.A. Recent Development Table 76. Novartis AG Company Information Table 77. Novartis AG Business Overview Table 78. Novartis AG PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio Table 80. Novartis AG Recent Development Table 81. Merck & Co., Inc. Company Information Table 82. Merck & Co., Inc. Business Overview Table 83. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 85. Merck & Co., Inc. Recent Development Table 86. Eli Lilly & Company Company Information Table 87. Eli Lilly & Company Business Overview Table 88. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 90. Eli Lilly & Company Recent Development Table 91. Pfizer Inc. Company Information Table 92. Pfizer Inc. Business Overview Table 93. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 95. Pfizer Inc. Recent Development Table 96. Jiangsu HengRui Medicine Co., Ltd. Company Information Table 97. Jiangsu HengRui Medicine Co., Ltd. Business Overview Table 98. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 100. Jiangsu HengRui Medicine Co., Ltd. Recent Development Table 101. GlaxoSmithKline plc Company Information Table 102. GlaxoSmithKline plc Business Overview Table 103. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 105. GlaxoSmithKline plc Recent Development Table 106. Regeneron Pharmaceuticals Inc. Company Information Table 107. Regeneron Pharmaceuticals Inc. Business Overview Table 108. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 110. Regeneron Pharmaceuticals Inc. Recent Development Table 111. Innovent Biologics, Inc. Company Information Table 112. Innovent Biologics, Inc. Business Overview Table 113. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 115. Innovent Biologics, Inc. Recent Development Table 116. F. Hoffmann-La Roche Ltd Company Information Table 117. F. Hoffmann-La Roche Ltd Business Overview Table 118. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio Table 120. F. Hoffmann-La Roche Ltd Recent Development Table 121. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information Table 122. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview Table 123. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 125. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development Table 126. Bristol-Myers Squibb Company Company Information Table 127. Bristol-Myers Squibb Company Business Overview Table 128. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 130. Bristol-Myers Squibb Company Recent Development Table 131. BeiGene, Ltd. Company Information Table 132. BeiGene, Ltd. Business Overview Table 133. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 135. BeiGene, Ltd. Recent Development Table 136. AstraZeneca Plc Company Information Table 137. AstraZeneca Plc Business Overview Table 138. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 140. AstraZeneca Plc Recent Development Table 141. North America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 143. North America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 144. North America PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032) & (K Units) Table 145. North America PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Country (2027-2032) Table 146. North America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 148. North America PD-1&PD-L1 Immunotherapy Market Share by Country (2021-2026) Table 149. North America PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America PD-1&PD-L1 Immunotherapy Market Share Forecast by Country (2027-2032) Table 151. Europe PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 153. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 154. Europe PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032) & (K Units) Table 155. Europe PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Country (2027-2032) Table 156. Europe PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe PD-1&PD-L1 Immunotherapy Market Share by Country (2021-2026) Table 159. Europe PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe PD-1&PD-L1 Immunotherapy Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 163. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032) & (K Units) Table 165. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Share by Country (2021-2026) Table 169. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Share Forecast by Country (2027-2032) Table 171. Latin America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 173. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 174. Latin America PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032) & (K Units) Table 175. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America PD-1&PD-L1 Immunotherapy Market Share by Country (2021-2026) Table 179. Latin America PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America PD-1&PD-L1 Immunotherapy Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 183. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032) & (K Units) Table 185. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Share by Country (2021-2026) Table 189. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. PD-1&PD-L1 Immunotherapy Distributors List Table 194. PD-1&PD-L1 Immunotherapy Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. PD-1&PD-L1 Immunotherapy Image Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1&PD-L1 Immunotherapy Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1&PD-L1 Immunotherapy Sales (2021-2032) & (K Units) Figure 5. PD-1 Inhibitors Image Figure 6. Global PD-1 Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. PD-L1 Inhibitors Image Figure 8. Global PD-L1 Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global PD-1&PD-L1 Immunotherapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global PD-1&PD-L1 Immunotherapy Market Share by Type 2025 VS 2032 Figure 11. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2025 Figure 12. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2025 Figure 13. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2025 Figure 14. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2025 Figure 17. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2025 Figure 18. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 PD-1&PD-L1 Immunotherapy Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Non-Small Cell Lung Cancer Image Figure 24. Global Non-Small Cell Lung Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hepatocellular Carcinoma Image Figure 26. Global Hepatocellular Carcinoma Sales YoY Growth (2021-2032) & (K Units) Figure 27. Urothelial Carcinoma Image Figure 28. Global Urothelial Carcinoma Sales YoY Growth (2021-2032) & (K Units) Figure 29. Esophageal Cancer Image Figure 30. Global Esophageal Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Small Cell Lung Cancer Image Figure 32. Global Small Cell Lung Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global PD-1&PD-L1 Immunotherapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global PD-1&PD-L1 Immunotherapy Market Share by Application 2025 VS 2032 Figure 37. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2025 Figure 38. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2025 Figure 39. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2025 Figure 40. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2025 Figure 43. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2025 Figure 44. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2025 Figure 47. North America PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America PD-1&PD-L1 Immunotherapy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America PD-1&PD-L1 Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe PD-1&PD-L1 Immunotherapy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe PD-1&PD-L1 Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific PD-1&PD-L1 Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America PD-1&PD-L1 Immunotherapy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America PD-1&PD-L1 Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. PD-1&PD-L1 Immunotherapy Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. PD-1&PD-L1 Immunotherapy Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Esophageal Cancer
  • Small Cell Lung Cancer
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.
  • Innovent Biologics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • AstraZeneca Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1&PD-L1 Immunotherapy Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PD-1&PD-L1 Immunotherapy Market by Type
  6. 1.3.1 PD-1 Inhibitors
  7. 1.3.2 PD-L1 Inhibitors
  8. 1.4 Global PD-1&PD-L1 Immunotherapy Market Size by Type
  9. 1.4.1 Global PD-1&PD-L1 Immunotherapy Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PD-1&PD-L1 Immunotherapy Industry Trends
  2. 2.2 PD-1&PD-L1 Immunotherapy Industry Drivers
  3. 2.3 PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
  4. 2.4 PD-1&PD-L1 Immunotherapy Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PD-1&PD-L1 Immunotherapy Revenue (2021-2026)
  2. 3.2 Global Top Players by PD-1&PD-L1 Immunotherapy Sales (2021-2026)
  3. 3.3 Global Top Players by PD-1&PD-L1 Immunotherapy Price (2021-2026)
  4. 3.4 Global PD-1&PD-L1 Immunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1&PD-L1 Immunotherapy Major Company Production Sites & Headquarters
  6. 3.6 Global PD-1&PD-L1 Immunotherapy Company, Product Type & Application
  7. 3.7 Global PD-1&PD-L1 Immunotherapy Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1&PD-L1 Immunotherapy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1&PD-L1 Immunotherapy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1&PD-L1 Immunotherapy Tier 1, Tier 2, and Tier 3
4 PD-1&PD-L1 Immunotherapy Regional Status and Outlook
  1. 4.1 Global PD-1&PD-L1 Immunotherapy Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size by Region
  3. 4.2.1 Global PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PD-1&PD-L1 Immunotherapy Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PD-1&PD-L1 Immunotherapy Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Region
  7. 4.3.1 Global PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PD-1&PD-L1 Immunotherapy Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PD-1&PD-L1 Immunotherapy Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PD-1&PD-L1 Immunotherapy by Application
  1. 5.1 PD-1&PD-L1 Immunotherapy Market by Application
  2. 5.1.1 Non-Small Cell Lung Cancer
  3. 5.1.2 Hepatocellular Carcinoma
  4. 5.1.3 Urothelial Carcinoma
  5. 5.1.4 Esophageal Cancer
  6. 5.1.5 Small Cell Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global PD-1&PD-L1 Immunotherapy Market Size by Application
  9. 5.2.1 Global PD-1&PD-L1 Immunotherapy Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi S.A.
  2. 6.1.1 Sanofi S.A. Company Information
  3. 6.1.2 Sanofi S.A. Business Overview
  4. 6.1.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
  6. 6.1.5 Sanofi S.A. Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Merck & Co., Inc.
  14. 6.3.1 Merck & Co., Inc. Company Information
  15. 6.3.2 Merck & Co., Inc. Business Overview
  16. 6.3.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  18. 6.3.5 Merck & Co., Inc. Recent Developments
  19. 6.4 Eli Lilly & Company
  20. 6.4.1 Eli Lilly & Company Company Information
  21. 6.4.2 Eli Lilly & Company Business Overview
  22. 6.4.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
  24. 6.4.5 Eli Lilly & Company Recent Developments
  25. 6.5 Pfizer Inc.
  26. 6.5.1 Pfizer Inc. Company Information
  27. 6.5.2 Pfizer Inc. Business Overview
  28. 6.5.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  30. 6.5.5 Pfizer Inc. Recent Developments
  31. 6.6 Jiangsu HengRui Medicine Co., Ltd.
  32. 6.6.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
  33. 6.6.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
  34. 6.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  36. 6.6.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
  37. 6.7 GlaxoSmithKline plc
  38. 6.7.1 GlaxoSmithKline plc Company Information
  39. 6.7.2 GlaxoSmithKline plc Business Overview
  40. 6.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
  42. 6.7.5 GlaxoSmithKline plc Recent Developments
  43. 6.8 Regeneron Pharmaceuticals Inc.
  44. 6.8.1 Regeneron Pharmaceuticals Inc. Company Information
  45. 6.8.2 Regeneron Pharmaceuticals Inc. Business Overview
  46. 6.8.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  48. 6.8.5 Regeneron Pharmaceuticals Inc. Recent Developments
  49. 6.9 Innovent Biologics, Inc.
  50. 6.9.1 Innovent Biologics, Inc. Company Information
  51. 6.9.2 Innovent Biologics, Inc. Business Overview
  52. 6.9.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  54. 6.9.5 Innovent Biologics, Inc. Recent Developments
  55. 6.10 F. Hoffmann-La Roche Ltd
  56. 6.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 6.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 6.10.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
  60. 6.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 6.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  62. 6.11.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
  63. 6.11.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
  64. 6.11.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  66. 6.11.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
  67. 6.12 Bristol-Myers Squibb Company
  68. 6.12.1 Bristol-Myers Squibb Company Company Information
  69. 6.12.2 Bristol-Myers Squibb Company Business Overview
  70. 6.12.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
  72. 6.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 6.13 BeiGene, Ltd.
  74. 6.13.1 BeiGene, Ltd. Company Information
  75. 6.13.2 BeiGene, Ltd. Business Overview
  76. 6.13.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  78. 6.13.5 BeiGene, Ltd. Recent Developments
  79. 6.14 AstraZeneca Plc
  80. 6.14.1 AstraZeneca Plc Company Information
  81. 6.14.2 AstraZeneca Plc Business Overview
  82. 6.14.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
  84. 6.14.5 AstraZeneca Plc Recent Developments
7 North America by Country
  1. 7.1 North America PD-1&PD-L1 Immunotherapy Sales by Country
  2. 7.1.1 North America PD-1&PD-L1 Immunotherapy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  4. 7.1.3 North America PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032)
  5. 7.2 North America PD-1&PD-L1 Immunotherapy Market Size by Country
  6. 7.2.1 North America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026)
  8. 7.2.3 North America PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PD-1&PD-L1 Immunotherapy Sales by Country
  2. 8.1.1 Europe PD-1&PD-L1 Immunotherapy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  4. 8.1.3 Europe PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PD-1&PD-L1 Immunotherapy Market Size by Country
  6. 8.2.1 Europe PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026)
  8. 8.2.3 Europe PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Country
  2. 9.1.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size by Country
  6. 9.2.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PD-1&PD-L1 Immunotherapy Sales by Country
  2. 10.1.1 South America PD-1&PD-L1 Immunotherapy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  4. 10.1.3 South America PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032)
  5. 10.2 South America PD-1&PD-L1 Immunotherapy Market Size by Country
  6. 10.2.1 South America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026)
  8. 10.2.3 South America PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country
  2. 11.1.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country
  6. 11.2.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PD-1&PD-L1 Immunotherapy Value Chain Analysis
  2. 12.1.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PD-1&PD-L1 Immunotherapy Production Mode & Process
  7. 12.2 PD-1&PD-L1 Immunotherapy Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PD-1&PD-L1 Immunotherapy Distributors
  10. 12.2.3 PD-1&PD-L1 Immunotherapy Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst